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 Abstract 
Dengue fever, a neglected emerging disease for which no vaccine or antiviral agents exist at present, is caused by 
dengue virus, a member of the Flavivirus genus, which includes several important human pathogens, such as yellow fever 
and West Nile viruses. The NS5 protein from dengue virus is bifunctional and contains 900 amino acids. The S-adenosyl 
methionine transferase activity resides within its N-terminal domain, and residues 270 to 900 form the RNA-dependent 
RNA polymerase (RdRp) catalytic domain. Viral replication begins with the synthesis of minus-strand RNA from the 
dengue virus positive-strand RNA genome, which is subsequently used as a template for synthesizing additional plus-strand 
RNA genomes. This essential function for the production of new viral particles is catalyzed by the NS5 RdRp.  
In this scenario, the present study aims to identify new molecules which could block or suppress the activity of 
RNA dependent RNA polymerase enzyme by molecular docking studies using AutodockVina. In this study we used in 
silico approach by modeling NS5 protein, Optimization of the structure was done by adding polar hydrogens and Kollman 
charges using Pyrx. We further carried out docking studies by means of Autodock Vina, with various phytochemicals. 
Based on binding energy, phytochemicals were screened and their interaction with NS5 was identified. Thus, we report 
Rohitukine alkaloid that has successfully satisfied all in silico parameters, necessitating further in vitro and in vivo studies. 
The improved conditions and new structural information should accelerate structure-based design of antiviral compounds 
against Dengue virus.   
Keywords: Flavivirus; dengue virus; NS5 polymerase, Molecular Docking, AutoDock/Vina, Medicinal Plants, Alkaloid. 
1. Introduction  
Dengue fever is an ancient disease that was first 
recorded in a Chinese encyclopedia of diseases and 
symptoms published during the Chin Dynasty (265 to 420 
AD)[1]. Infection by DENV can be asymptomatic or result 
in a variety of clinical manifestations ranging from 
comparatively mild dengue fever (DF) to severe disease 
such as dengue haemorrhagic fever (DHF) and dengue 
shock syndrome (DSS) [2,3]. 
DENV poses a major risk for human health. It is 
estimated that half of the population of the world is at risk 
of becoming infected with one serotype of DENV or 
another [4]. Recent data indicated that in 2013, DENV 
caused 40–58 million symptomatic infections, including 
13,586 fatal cases, with an associated financial cost of US$ 
8.9 billion [5]. DENV infection in humans develops 
differently in each case. Globally, in 2013, 18% of DENV-
infected patients were admitted to hospital, 48% received 
medical attention or advice outside a hospital, and 34% did 
not need, find, or seek medical attention [5]. 
The genome is single-stranded, positive-sense 
RNA about 11 kbp, including a 5’type I cap (m7 Gppp), 
and a 3’ terminus lacking a poly-A tail [6]. It contains a 
single open reading frame encoding 10 proteins: 3 structural 
proteins (C, prM and E) and 7 non-structural proteins (NS1, 
NS2a, NS2b, NS3, NS4a, NS4b, and NS5) (Figure 1). This 
single polyprotein is subsequently cleaved by host and viral 
enzymes. 
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Figure 1: Dengue viral genome [7] 
 
NS5 is the largest (102 kDa) and the most 
conserved protein (with ~70% sequence identity among the 
four serotypes, see Figure 2 a) [8] expressed during 
infection by dengue virus. It carries two domains: a 
methyltransferase domain (MTase) at its N-terminal end 
and a RNA-dependent RNA polymerase (RdRp) at its C-
terminus (Figure 2b). The architecture of the NS5 protein is 
well conserved across flaviviruses as confirmed by the 
recent crystal structure determination of the ZIKVNS5 
protein [9-12]. This high level of structure conservation 
suggests that it is possible to design compounds targeting 
NS5 with broad activity against several flaviviruses. The C-
terminal domain (276–900) contains the RdRp enzymatic 
motifs. Because the RdRp activity is absent in the host cell, 
NS5 represents a promising antiviral target to design 
specific inhibitors with low toxicity. In addition to its rolein 
replicating the viral genome, NS5 can also down-regulate 
the host immune interferon response, via its interaction with 
the signal transducer and activator of transcription 2 
(STAT2) proteins [13] or, as proposed recently, by 
modulating RNA splicing within the host cell [14]. 
Phytochemicals are found abundantly in Medicinal 
Plants [15]. These phytochemicals act as a strong defense 
mechanism forplants and also safeguard human bodies and 
animals against various contagious viruses and epidemics 
[16]. A broad range of phytochemicals can be traced in 
medicinal plants including organosulfur compounds, 
limonoids, furyl compounds, alkaloids, polyines, 
coumarins, thiophenes, peptides, flavonoids, terpenoids, 
polyphenolics and saponins. These phytochemicals serves 
their remedial function by scavenging and hindering viral 
entry and DNA\RNA replication against a wide range of 
viruses [17]. Treatment of Dengue Virus with medicinal 
plant costs less as compared to good old traditional methods 
[18]. It may also be preferred because of the multiple target 
activities, little probable to cause resistance and nominal 
side-effects [19]. In this context, we performed an in silico 
study to find new potential NS5 RdRp efficient agonists 
from a chemical library of South African Natural 
Compound Database (SANCDB), Maps database, Super 
Natural database. Our in silico approach provides the basis 
for subsequent in vitro and in vivo studies to test these 
newly identified DENV NS5 RdRp inhibitor candidates. 
 
 
Figure 2: a). Sequence alignment of dengue virus (DENV) NS5 proteins from the four serotypes. Sequence numbering is 
according to DENV2 NS5. Secondary structure assignment follows the DENV3 NS5 full‐length protein structure (Protein 
Data Bank (PDB) access code 4V0Q). Specific sequence motifs (A–F) are labeled in red. The linker region is indicated in 
green. The recently characterized nuclear localization signal is colored in light blue and the priming loop in blue. 
(b). Superimposition between DENV 3 NS5 (4V0Q, light blue) and Zika virus (ZIKV) NS5 (5TFR, purple) full‐length 
protein structure is represented as carbon traces. MTase: methyltransferase; RdRP: RNA‐dependent RNA polymerase. 
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2. Material and methods 
This study involves the docking of 1371 
phytochemicals of antiviral medicinal plants against 
Dengue virus NS5 protein. This data has been taken from 
South African Natural Compound Database (SANCDB), 
Maps database, Super Natural database. Autodockvina in 
Pyrx software package was used to carry out docking. 
2.1 Receptor refinement 
Three dimensional structure of NS5 was retrieved 
from the database of Protein Data Bank (PDB) using PDB 
id 2j7w (figure 3). PDB ID was converted into required 
PDBQT format .Optimization of the structure was done by 
adding polar hydrogens and Kollman charges using Pyrx. 
To optimize the structure H2O molecules were removed 
from the structure and 3D protonation was done to change 
the state into ionization level. 
2.2 Alkaloid refinement 
All the alkaloids were optimized by adding 
hydrogens using Openbabel in Pyrx software. All these 
alkaloid were saved in PDBQT which was further used for 
docking studies. 
2.3 Molecular docking 
The docking algorithem of Autodockvina software 
was used to dock these phytochemicals with catalytic site of 
NS5. Generation of 3D structure, energy minimization, and 
conversion into PDBQT format was carried out using 
OPEN BABEL in PYRX. All single bonds were allowed to 
have free rotation. Grid parameters were optimized, 
dimensions (Angstrom) of vina search space were set to 
default of 25x25x25 with center X: 32.49 Y:60.86 Z:16.01 
and exhaustiveness 8. For molecular visualization, docking 
poses generated by AutoDockVina were directly loaded 
into PyMol through PyMol Autodock/Vina Plugin. Pictures 
of the modeled protein-ligands complex were produced by 
PyMol. Docking programme of Autodockvina provides 
correct conformation of the ligand so as to obtain minimum 
energy structure. Top conformation of each phytochemical 
was selected on the basis of binding energy and were 
further evaluated to study the hydrogen bonding 
interactions. 
 
3. Results 
The 3D xray crystallographic structure of DENV 
NS5 was retrieved using PDB id 2j7w which was having 
resolution of 1.85 Angstrom (20). All phytochemicals were 
docked with the catalytic site of NS5 RNA dependent RNA 
polymerase domain. 
 
Figure 3-Crystal Structure of the Dengue Virus RNA- 
Dependent RNA Polymerase Catalytic Domain at 1.85 
Angstrom Resolution (20). 
3.1 Molecular Docking  
Autodockvina docking programe provided 
conformation of each phytochemicals. All the 
conformations were sorted according to binding energy and 
top ranking conformation with minimum binding energy 
were further analyzed. Alkaloid Rohitukine was ranked as 
top conformation (Table 1). 
Table 1:  Molecular docking analysis for potential inhibitor compounds at the binding site of NS5 RdRp 
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3.3 Interaction analysis 
Out of 1371 selected phytochemicals used for 
interaction analysis only 1 alkaloid Rohitukine (other 
names- 5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-
yl)-2-methylchromen-4-one) has shown significant 
interactions with Ser 661, Asp 663, Asp 664 and bound 
deeply inside the binding pocket (figure 5). 
 
 
 
Figure 4: Chemical structure of selected alkaloid is 
shown in figure (PubChem CID- 5387431) 
 
Figure 5: Docked Rohitukine complex with DENV NS5 
pocket 
3.4 Drug scan 
Final selected alkaloid compound was analyzed 
using the Ligand properties checking tool of MOE which 
assessed the molecular properties and practicability of these 
compounds of being drug candidates on the basis of 
“Lipinski’s Rule of Five”[30]. The rule describes molecular 
properties important for a drug’s pharmacokinetics in the 
human body, including their absorption, distribution, 
metabolism and excretion. This Compound was examined 
for their drug-suitableness and the results are shown in 
Table. Our results showed that   the alkaloid compound 
used in this study fulfill the criteria of being drug 
candidates (Table 2). 
 
Table 2: Molecular properties of alkaloid assessed through Ligand properties checking tool of MOE 
Phytochemical Name 
Molecular 
Formula 
Molecular 
Weight 
LogP TPSA 
Hydrogen 
Bond donor 
Hydrogen 
bond acceptor 
Lipinski’s 
rule of five 
Rohitukine C16H19NO5 305.33 g/mol 1.4 90.2A^2 3 6 Suitable 
 
4. Discussion 
We performed this study to identify and 
characterise the inhibitory potential of the Rohitukine 
alkaloid against DENV NS5. The results of the protein-
protein docking study showed that the Rohitukine alkaloid 
bound to the NS5 by hydrophobic residue interactions with 
Ser 661, Asp 663, and Asp 664. The binding of Rohitukine 
to NS5 may effectively inhibit binding of the substrate to 
the active site. Therefore, inhibition of dengue NS5 may 
directly lead to inhibition of the replication process of the 
viral polyprotein and subsequent virus replication. 
 
5. Conclusion 
Current study focuses on the assessment of 
alkaloid Rohitukine from medicinal plants as drug 
candidate against NS5. Molecular docking of alkaloid 
against NS5 has revealed strong interactions between 
alkaloid Rohitukine (5,7-dihydroxy-8-(3-hydroxy-1-
methylpiperidin-4-yl)-2-methylchromen-4-one) and the 
active site of NS5. The information acquired through this 
study on the binding mode of alkaloid and NS5 will highly 
facilitate the synthesis and testing of alkaloid Rohitukine as 
drug against DENV. On a concluding note, this study has 
suggested that Rohitukine will be strong future drug 
candidates against DENV. 
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